A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Summary

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Eligibility

Inclusion Criteria:

* Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
* EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
* Documented MRI of brain with abnormalities consistent with MS before screening

Exclusion Criteria:

* Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
* History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
* Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
* History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
* Inability to complete an MRI scan or contraindication to Gd administration
* Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
* Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
* Known history of human immunodeficiency virus (HIV) infection
* Lack of peripheral venous access
* Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
* Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)

Conditions3

Interventions1

Related trials

• A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis — Biocad
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) — Hoffmann-La Roche
• A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) — Hoffmann-La Roche
• An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment — Hoffmann-La Roche
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Novartis Pharmaceuticals
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis — National Institute of Allergy and Infectious Diseases (NIAID)
• Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University
• A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies — Biogen

Browse More Trials